{
  "schema_version": "1.0",
  "last_updated": "2026-07-08",
  "description": "Editorial, evidence-weighted scoring rubric for compounded tirzepatide telehealth providers. Providers cannot pay for placement.",
  "factors": [
    {
      "factor": "clinical_oversight",
      "weight": 0.2,
      "assesses": "Licensed-clinician review of every intake; ability to reach a prescriber; dose-adjustment support"
    },
    {
      "factor": "pharmacy_transparency",
      "weight": 0.15,
      "assesses": "Whether the provider names its 503A/503B compounding pharmacy and sourcing"
    },
    {
      "factor": "evidence_based_protocols",
      "weight": 0.15,
      "assesses": "Titration schedules and clinical practices consistent with trial evidence and labeling"
    },
    {
      "factor": "published_outcomes",
      "weight": 0.1,
      "assesses": "Transparency about expected results grounded in published trial data"
    },
    {
      "factor": "price_transparency",
      "weight": 0.1,
      "assesses": "Clear upfront pricing with no hidden membership or consultation fees"
    },
    {
      "factor": "total_cost_through_maintenance",
      "weight": 0.1,
      "assesses": "Real annual cost once titrated to an effective dose"
    },
    {
      "factor": "regulatory_compliance",
      "weight": 0.1,
      "assesses": "Accurate not-FDA-approved disclosure and safety warnings"
    },
    {
      "factor": "patient_support",
      "weight": 0.1,
      "assesses": "Access to clinical support, responsiveness, continuity of care"
    },
    {
      "factor": "independent_reputation",
      "weight": 0.05,
      "assesses": "Third-party review signals, weighted cautiously"
    },
    {
      "factor": "technology_monitoring",
      "weight": 0.05,
      "assesses": "Platform quality, lab integration, ongoing monitoring"
    }
  ],
  "note": "Where independently verified data for a factor is unavailable, it is not scored or asserted."
}